Morecambe

Researchers are studying Cancer of Unknown Primary CUP, a condition where cancer cells are present but the original tumor site is unknown. CUP is a common cause of cancer death with limited treatment options and a poor prognosis. This research aims to better understand the molecular characteristics of CUP by exploring the use of liquid biopsies, which analyze DNA from blood samples, as a new way to identify biomarkers and guide potential therapies. Participants will provide blood samples for gene panel array testing and research purposes. This study involves collecting blood on up to two occasions to perform molecular profiling. The study will recruit for 33 months, followed by a 12-month follow-up period or until December 1, 2027, whichever comes first. The goal is to assess how useful cell-free DNA cfDNA profiling is for patients with CUP and to integrate molecular genomics into routine clinical practice. During the study, participants will be monitored through collection of blood samples and their tumor histological reports will be reviewed. Data about treatments and trials for CUP will be gathered and genomic results will be shared with treating teams and patients. The study is observational and involves no experimental treatments. Participants are expected to consent and have an ECOG performance status of 0 to 2, allowing them to undergo blood sampling and follow-up over the course of the study.